Moderate

CKD-mineral and bone disorder (CKD-MBD)

CKD-MBD · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Disturbed calcium, phosphate, PTH and vitamin D metabolism in CKD driving secondary hyperparathyroidism, vascular calcification and renal osteodystrophy. Management targets phosphate control, vitamin D repletion and PTH suppression rather than normalising every number.

Red flags

  • Painful violaceous skin plaques/necrosis suggesting calciphylaxis
  • Severe symptomatic hypercalcaemia
  • Pathological fracture or severe bone pain
  • Rapidly rising PTH with hypercalcaemia (tertiary hyperparathyroidism)
  • Extensive vascular/cardiac valve calcification

Assessment

Differential diagnosis

  • Secondary hyperparathyroidism of CKD
  • Tertiary (autonomous) hyperparathyroidism
  • Adynamic bone disease (over-suppressed PTH)
  • Osteomalacia / vitamin D deficiency
  • Primary hyperparathyroidism
  • Aluminium bone disease (rare)

Investigations

  • Corrected calcium, phosphate, ALP
  • Intact PTH (trend, not single value)
  • 25-OH vitamin D
  • eGFR and CKD stage
  • Bicarbonate (acidosis worsens bone loss)
  • Lateral abdominal X-ray / echo for vascular calcification if considering therapy change

Management

  • Stage CKD and establish baseline Ca, PO4, PTH, 25-OH vitamin D and ALP; monitor frequency by stage (G3 6-12 monthly, G4 3-6 monthly, G5/dialysis 1-3 monthly)
  • Treat hyperphosphataemia first with dietary phosphate restriction (800-1000 mg/day, limit additives/processed foods) and dietitian referral
  • Add oral phosphate binder taken with meals if phosphate persistently elevated; prefer non-calcium binders (sevelamer, lanthanum) where calcium load or vascular calcification is a concern
  • Correct 25-OH vitamin D deficiency with colecalciferol before using active analogues
  • Avoid routine normalisation of mildly low calcium; treat symptomatic or progressive hypocalcaemia
  • For persistently high/rising PTH despite phosphate and vitamin D correction, add active vitamin D (alfacalcidol or calcitriol) at low dose and titrate
  • In dialysis patients with refractory secondary hyperparathyroidism add a calcimimetic (cinacalcet or IV etelcalcetide)
  • Correct metabolic acidosis to bicarbonate >=22 mmol/L with oral sodium bicarbonate
  • Avoid oversuppressing PTH (risk of adynamic bone); keep dialysis PTH roughly 2-9x upper limit of normal
  • Refer for parathyroidectomy if severe refractory hyperparathyroidism, symptomatic hypercalcaemia, calciphylaxis or intractable pruritus
  • Screen for and manage calciphylaxis urgently if painful skin necrosis appears
  • Reassess bone/mineral targets and medication burden at each review

Drugs & doses

Colecalciferol 20,000-50,000 units PO weekly (deficiency), then 800-2000 units PO daily maintenance
Sevelamer carbonate 800-2400 mg PO three times daily with meals
Lanthanum carbonate 500-1000 mg PO three times daily chewed with meals
Calcium acetate 1000 mg PO three times daily with meals (if calcium-based binder appropriate)
Alfacalcidol 250-500 nanograms PO daily, titrated to PTH
Cinacalcet 30 mg PO daily initially, titrate to max 180 mg daily
Sodium bicarbonate 500-1000 mg PO two to three times daily for acidosis

Disposition

Outpatient nephrology/CKD clinic management; dietitian input. Refer to endocrine surgery for parathyroidectomy in refractory disease. Admit urgently for calciphylaxis or severe symptomatic hypercalcaemia.

Complications & pitfalls

  • Renal osteodystrophy and fractures
  • Vascular and valvular calcification, cardiovascular death
  • Calciphylaxis
  • Tertiary hyperparathyroidism needing surgery
  • Adynamic bone disease from oversuppression
  • Soft-tissue calcification and pruritus

Exam pearls

  • Control phosphate and vitamin D before chasing PTH down
  • Avoid high calcium loads where vascular calcification is a concern
  • A single PTH is less useful than the trend
  • Oversuppressed PTH (adynamic bone) is as harmful as high PTH
  • Phosphate binders only work if taken with food

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.